1 It has been reported that co-administration of¯uoxetine with 3,4-methylenedioxymethamphetamine (MDMA,`ecstasy') prevents MDMA-induced degeneration of 5-HT nerve endings in rat brain. The mechanisms involved have now been investigated. , 62) failed to alter cerebral MDMA accumulation compared to saline pretreated controls. 6 Neither¯uoxetine or¯uvoxamine altered MDMA-induced acute hyperthermia. 7 These data demonstrate that¯uoxetine produces long-lasting protection against MDMA-induced neurodegeneration, an eect apparently related to the presence of the drug and its active metabolite inhibiting the 5-HT transporter. Fluoxetine does not alter the metabolism of MDMA or its rate of cerebral accumulation.
Introduction
The recreationally used drug 3,4-methylenedioxymethamphetamine (MDMA or`ecstasy') has two distinct neurochemical eects on the concentration of 5-hydroxytryptamine (5-HT) in the brain of rats. The ®rst eect is a rapid and dramatic increase in the extracellular concentration of 5-HT. This results from the ability of MDMA to stimulate 5-HT release (Gough et al., 1991; Brodkin et al., 1993) , inhibit uptake (Steele et al., 1987; Johnson et al., 1991) and block metabolism of 5-HT by MAO-A (Leonardi & Azmitia, 1994) . MDMA binds with high anity to the 5-HT transporter protein (Poblete et al., 1989) , reverses the direction of neurotransmitter¯ow (Rudnick & Wall, 1992) and exerts a pronounced stimulatory eect on 5-HT release in synaptosomes (Nichols et al., 1982; McKenna et al., 1991; Berger et al., 1992) , brain slices (Johnson et al., 1986; Sprouse et al., 1989; Fitzgerald & Reid, 1993) and cultured neurones (Azmitia et al., 1990; Gu & Azmitia, 1993) . 5-HT release has also been demonstrated in vivo by the use of intracerebral microdialysis Gough et al., 1991; Gudelsky & Nash, 1996) . The acute 5-HT releasing eect of MDMA involves both a calcium-dependent mechanism (Crespi et al., 1997) and a calcium independent process mediated by the transporter (Johnson et al., 1986) . In fact, the release of 5-HT induced by MDMA in vivo is mostly attenuated by drugs that bind to the 5-HT transporter (¯uoxetine, citalopram) thereby inhibiting the 5-HT uptake into presynaptic terminals (Schmidt, 1987; Schmidt et al., 1987; Azmitia et al., 1990; Hekmatpanah & Peroutka, 1990; Gudelsky & Nash, 1996; Mechan et al., 2000) . The eect of MDMA on 5-HT release is reversible, the 5-HT extracellular concentration returning to control values 3 ± 4 h after drug administration (Gudelsky & Nash, 1996; Mechan et al., 2000) . Simultaneously with the 5-HT release, rats display both the 5-HT behavioural syndrome and hyperthermia (Slikker et al., 1989; Colado et al., 1993) .
The second action of MDMA is that of producing, in several areas of the brain, a long-term loss of ®ne 5-HT axon terminals arising primarily from the dorsal raphe nucleus (O'Hearn et al., 1988) . The degeneration has been demonstrated both histologically (O'Hearn et al., 1988; Molliver et al., 1990 ) and biochemically and is re¯ected in a substantial decrease in the concentration of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), and a reduction in the density of 5-HT uptake sites labelled with [ 3 H]-paroxetine (Sharkey et al., 1991; Hewitt & Green, 1994; Colado et al., 1997b) .
The mechanisms involved in producing this neurodegeneration are not fully understood at present, but recent data indicate that a major mechanism by which MDMA induces damage to 5-HT containing neurones in rat brain is by increasing the formation of hydroxyl free radicals Colado et al., 1997b; Yeh, 1999) which probably result from MDMA metabolism . The use of intracerebral microdialysis has demonstrated that systemic administration of MDMA increases the formation of 2,3-dihydroxybenzoic acid (2,3-DHBA) from salicylate in hippocampal and striatal dialysates (Colado et al., 1997b; Shankaran et al., 1999) , a conversion that only occurs in the presence of a high concentration of free radicals. The fact that this eect was absent in rats with a lesion of the 5-HT nerve terminals indicates that these reactive species are probably formed in 5-HT nerve endings (Colado et al., 1997b) . Additional evidence supporting the existence of an oxidative stress includes the report that the hydroxyl radical scavenger alpha-phenyl-N-tert-butyl nitrone (PBN) is neuroprotective Colado et al., 1997b; Yeh, 1999) and also abolishes the MDMAinduced rise in 2,3-DHBA (Colado et al., 1997b) , the observation that MDMA increases lipid peroxidation in the brain (Sprague & Nichols, 1995; Colado et al., 1997a) and the fact that transgenic mice overexpressing CuZn superoxide dismutase are resistant to the neurotoxic actions of the drug (Cadet et al., 1995) .
Initial studies based on both the pharmacology of MDMA and putative neuroprotective compounds, suggested a key role for dopamine in the expression of MDMA-induced neurotoxicity (Stone et al., 1988; Schmidt et al., 1990; Hewitt & Green, 1994) . Most of these studies were performed in the absence of measures of body temperatures and consequently, a re-evaluation of the earlier reports was necessary. There is now evidence that a-methy-p-tyrosine and haloperidol only prevent MDMA-induced damage because they either induce hypothermia (Malberg et al., 1996) or prevent acute hyperthermia (Colado et al., 1999) and that the enhancing eect of L-DOPA on MDMA-induced neurodegeneration (Schmidt et al., 1991) might result from its ability to increase the MDMA-induced hyperthermia (Colado et al., 1999) . In addition, the MAO-B inhibitor deprenyl has been shown to possess free radical scavenger activity (Thomas et al., 1997) which could explain its neuroprotective eect against MDMA toxicity (Sprague & Nichols, 1995) .
There is a large amount of evidence indicating the involvement of the 5-HT transporter in both the acute and in the long-term eects induced by MDMA. Fluoxetine, a selective 5-HT uptake inhibitor (Wong et al., 1983) , when given with MDMA, prevents both the acute increase in hydroxyl radical formation which follows administration of the amphetamine derivative (Shankaran et al., 1999) and the long-lasting neurotoxic eects (Schmidt, 1987; Malberg et al., 1996) . The neuroprotective eect of¯uoxetine does not depend on an eect on body temperature since animals treated with¯uoxetine and MDMA displayed a hyperthermic response similar to that observed when MDMA is given alone (Malberg et al., 1996; Mechan et al., 2000) . Since MDMA interacts with the 5-HT transporter protein (Poblete et al., 1989) it seems reasonable to propose that¯uoxetine may be preventing the uptake of MDMA or most likely, of a neurotoxic metabolite of MDMA into the 5-HT nerve endings (Malberg et al., 1996; Esteban et al., 2001) .
Fluoxetine is extensively biotransformed (N-demethylation) by the hepatic cytochrome P450 2D6 enzyme system to nor¯uoxetine (Bergstrom et al., 1992; Hamelin et al., 1996) , an active metabolite which is eliminated much more slowly than¯uoxetine by both rats and humans (Gardier et al., 1994; Hamelin et al., 1996; Holladay et al., 1998) . The plasma elimination half-lives of¯uoxetine and nor¯uoxetine are respectively in the range 1 ± 3 days and 7 ± 15 days (Lemberger et al., 1985; Ben®eld et al., 1986; Stanford, 1996; Preskorn, 1997; Sanchez & Hyttel, 1999) . Both compounds are highly lipophilic and accumulate in the brain where their concentrations are higher than those found in plasma (Gardier et al., 1994; Lefebvre et al., 1999) . Nor¯uoxetine is as potent as¯uoxetine in inhibiting 5-HT uptake and it is also more selective (Bolden-Watson & Richelson, 1993; Sanchez & Hyttel, 1999) . Its presence in vivo therefore probably contributes substantially to the pharmacological and therapeutic eects of the parent compound (Horng & Wong, 1976; Fuller et al., 1978; Schmidt, 1987) .
Fluvoxamine is also a selective 5-HT uptake inhibitor but with a dierent pharmacokinetic pro®le. Fluvoxamine undergoes oxidative metabolism but, in contrast to¯uoxetine, it generates several metabolites, none of which appear to be pharmacologically active. In addition, CYP2D6 isoenzymes do not play a signi®cant role in its metabolism (Van Harten, 1995; Preskorn, 1997) .
The aim of this current study was to examine the mechanisms involved in the neuroprotective eect of uoxetine against MDMA-induced neurotoxic loss of 5-HT in rat brain. To do this, MDMA was either coadministered with¯uoxetine or given several days (2, 4 and 7 days) later. In addition, the study also investigated whether the long-term neuroprotective eect of¯uoxetine was due to changes in the 5-HT transporter produced by the presence of either¯uoxetine or nor¯uoxetine or, alternatively, it resulted from a pharmacokinetic interaction between¯uoxetine and MDMA since, in rats, MDMA is metabolized to 3,4-dihydroxymethamphetamine (DHMA) by CYP2D1 and¯uoxetine and nor¯uoxetine are potent inhibitors of CYP2D1. This investigation has also examined whether the neuroprotection induced by¯uoxetine can be British Journal of Pharmacology vol 134 (1)
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Methods

Animals, drug administration and experimental protocol
All experimental procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication No. 85-23, revised 1985) . Male Dark Agouti rats (175 ± 200 g, Harlan Iberica, Barcelona) were used. They were housed in groups of ®ve, in conditions of constant temperature (21+28C) and a 12 h light/dark cycle (lights on: 0700 h) and given free access to food and water. (+) MDMA (obtained from the Ministry of Health, Spain),¯uoxetine (Lilly) and¯uvoxamine (Tocris) were dissolved in saline (0.9% NaCl) and given i.p. in a volume of 1 ml kg 71 for MDMA and¯uvoxamine and 2 ml kg 71 for¯uoxetine. Doses are reported in terms of the base.
Fluoxetine (10 mg kg
71
, i.p., twice, 60 min apart) was given 2, 4 and 7 days before MDMA (15 mg kg 71 , i.p.). In order to compare the neuroprotective eect of¯uoxetine after these pretreatment periods with that when the drug was coadministered with MDMA, a further group of animals received¯uoxetine 5 min before and 55 min after MDMA.
Fluvoxamine (15 mg kg
, i.p., twice, 60 min apart) was given either 24 h before MDMA (15 mg kg 71 , i.p) or 5 min before and 55 min after MDMA. Animals were always sacri®ced 7 days after MDMA administration.
Rats were given a single administration of MDMA at the dose of 15 mg kg 71 since previous studies had demonstrated that this regimen produced an approximately 50% loss of several 5-HT parameters (O'Shea et al., 1998) . Fluoxetine and uvoxamine were administered at doses altering the extracellular concentration of 5-HT (Bosker et al., 1995; Mechan et al., 2000) .
Measurement of rectal temperature
Temperature was measured during the 6 h following MDMA administration by means of a digital readout thermocouple (Type K thermometer, Portec, U.K.) with a resolution of+0.18C and accuracy of+0.28C attached to a CAC-005 Rodent Sensor which was inserted 2.5 cm into the rectum of the rat, the animal being lightly restrained by holding in the hand. A steady readout was obtained within 10 s of probe insertion.
Measurement of 5-HT and its metabolite, 5-HIAA, in cerebral tissue
Rats were killed by cervical dislocation and decapitation, the brains rapidly removed and cortex, hippocampus and striatum dissected out on ice. Tissue was homogenized and 5-HT and 5-HIAA measured by high performance liquid chromatography (h.p.l.c.). Brie¯y, the mobile phase consisted of KH 2 PO 4 (0.05 M), octanesulphonic acid (0.16 mM), ethylenediaminetetraacetic acid (EDTA, 0.1 mM) and methanol (16%), and was adjusted to pH 3 with phosphoric acid, ®ltered and degassed. The¯ow rate was 1.3 ml min 71 and the working electrode potential was set at +0.8 V.
The h.p.l.c. system consisted of a pump (Waters 510) linked to an automatic sample injector (Loop 200 ml, Waters 712 WISP), a stainless steel reversed-phase column (Spherisorb ODS2, 5 mm, 15064.6 mm) with a precolumn and an amperometric detector (Waters M460). The current produced was monitored by using an integrator (Waters M745).
Measurement of fluoxetine, norfluoxetine, fluvoxamine and MDMA in cerebral tissue
Cortical tissue was homogenized in ice-cold sodium carbonate-sodium bicarbonate buer (pH: 11.5) using an ultrasonicator. The homogenate was centrifuged at 18,000 r.p.m. for 20 min at 48C. The supernatant was applied to a 145 mg C8 endcapped SPE Light column (International Sorbent Technology, Waters). The column was washed with methanol (2 ml) followed by distilled H 2 O (2 ml) before sample (400 ml supernatant+250 ml distilled H 2 O+100 ml protriptiline (5 mg ml 71 ) or 100 ml¯uoxetine (10 mg ml 71 ) or 100 ml 3,4-methylenedioxyethylamphetamine (10 mg ml 71 ) as internal standards for¯uoxetine,¯uvox-amine and MDMA, respectively) was applied. The column was washed with H 2 O (2 ml) before selective elution of uoxetine, nor¯uoxetine,¯uvoxamine or MDMA with methanol (1 ml).
An aliquot (20 ml) of the resulting eluate was injected into a Waters h.p.l.c. system which consisted of a pump (Waters 510) linked to a manual sample injector (Loop 20 ml, Rheodyne), a stainless steel column (RP 18, 5 mm, 15064.6 mm, XTerra) with a precolumn (RP 18, 5 mm, 2063.9 mm, XTerra) and an ultraviolet/visible detector (Waters 2487). The current produced was monitored by using an integrator (Waters M745). For¯uoxetine and nor¯uoxetine analysis the mobile phase consisted of 20 mM potassium dihydrogen phosphate (65%) and acetonitrile (35%, pH 2.5); the¯ow rate was set to 1.5 ml min 71 and u.v. absorption was measured at 210 nm. The retention times were 6.1 min for protriptiline (internal standard), 8.4 min for nor¯uoxetine and 9.6 min for¯uoxetine. For uvoxamine analysis, the experimental conditions were the same as above and the¯ow rate was set to 1 ml min
71
. The retention times were 10.6 min for¯uvoxamine and 17.8 min for¯uoxetine (internal standard). For MDMA analysis the mobile phase consisted of 20 mM potassium dihydrogen phosphate (75%) and acetonitrile (25%, pH 2.5); the¯ow rate was set to 0.8 ml min 71 and u.v. absorption measured at 235 nm. The retention times were 4.3 min for MDMA and 5.2 min for 3,4-methylenedioxyethylamphetamine (internal standard). In each run all the peaks were completely resolved without any interference from endogenous compounds. Recoveries were determined by comparing peak height ratios of the extracted standards with those obtained by direct injection of the same amount of compounds ranged from 5 ± 40 mg ml 71 for¯uoxetine and nor¯uoxetine, from 2.5 ± 40 mg ml 71 for¯uvoxamine and from 1.25 ± 80 mg ml 71 for MDMA. The limit of detection under the described conditions was 10 pg ml 71 for all the compounds with a signal to noise ratio of 3. Intra-assay variation was less than 5% and recovery greater than 90% except for MDMA (75%). Hewitt & Green (1994) . The animals were killed, the brain rapidly removed and dissected on ice within 2 min. Cortex from individual animals was homogenized in ice-cold Tris-HCl (50 mM; pH 7.4) containing (in mM): NaCl 120 and KCl 5, using an Ultra-Turrax. The homogenate was centrifuged at 30,0006g for 10 min at 48C. The supernatant was discarded and the wash procedure repeated twice more. The pellet was ®nally resuspended in the Tris buer at a concentration of 5 mg tissue ml ; Du Pont) in the absence or presence of 5-HT for determination of non speci®c binding. The assay solution (1 ml) contained 100 ml of [ 3 H]-paroxetine (0.02 ± 4 nM) and 800 ml tissue preparation with the addition of either 100 ml 5-HT (100 mM) or 100 ml of buer. After incubation, assay was terminated by rapid ®ltration through Whatman GF/B ®lters pretreated with 0.05% polyethylenimine using the Skatron Cell Harvester. The radioactivity was counted by scintillation spectrometry. Protein concentration was measured by the method of Lowry et al. (1951) .
Statistics
Data from the monoamine and [ Statistical analysis of the temperature measurements were performed using the statistical computer package BMDP/ 386 Dynamic (BMDP Statistical Solutions, Cork, Eire). Data were analysed by means of two-way ANOVA with repeated measures (program 2 V) or, where missing values occurred, an unbalanced repeated measure model (program 5 V) was used. Both used treatment as the between subjects factor and time as the repeated measure. ANOVA was performed on both pre-treatment and post-treatment data.
Results
Effect of fluoxetine and fluvoxamine on the changes induced by MDMA in brain indole content and cortical 
Brain concentrations of fluoxetine, norfluoxetine and fluvoxamine
Following two doses of¯uoxetine (10 mg kg 71 , i.p., 60 min apart) the levels of both¯uoxetine and its main metabolite, nor¯uoxetine, were determined in cortex over the next 7 days. At the intervals examined, the peak concentration of uoxetine occurred within the ®rst 30 min interval declining progressively thereafter, reaching a low and constant concentration between 4 ± 7 days after dosing (Figure 4 ). Nor¯uoxetine concentrations rose over the ®rst 24 ± 48 h, the concentration then diminishing slowly over the next 5 days (Figure 4) .
The concentration of¯uvoxamine 30 min after the second of two doses of the drug (15 mg kg 71 , i.p. 60 min apart) was 35+6 nmol g 71 (n=4). The concentration then decreased rapidly, being 6+0.03 nmol g
71
(n=4) at 6 h and 3+0.2 nmol g 71 (n=4) at 24 h. 
Effect of fluoxetine on indole concentration in the brain
Discussion
This study shows for the ®rst time that¯uoxetine, when given 4 days before MDMA, provides complete protection against the delayed neurotoxic loss of 5-HT nerve terminals induced by this amphetamine derivative and still provides partial protection when given 7 days earlier. Other authors have previously reported that¯uoxetine protected against MDMA-induced neurodegeneration, but in their studies the 5-HT uptake inhibitor was co-administered with the MDMA (Schmidt, 1987; Malberg et al., 1996; Shankaran et al., 1999) or given up to 6 h later (Schmidt, 1987; Shankaran et al., 1999) . In the current study, protection was observed not only in the attenuation of the MDMAinduced decrease in 5-HT and 5-HIAA concentration in hippocampus, cortex and striatum, but also in the attenuation of the reduction in cortical 5-HT uptake sites (Habert et al., 1985) and MDMA (Hewitt & Green, 1994) . Therefore, the ability of¯uoxetine to attenuate the loss of 5-HT transporter gives con®dence in the conclusion that¯uoxetine is producing true neuroprotection.
When [ 3 H]-paroxetine binding was used as a marker rather than the 5-HT content, the degree of protection seen when uoxetine was given concurrently with MDMA was smaller than that observed when¯uoxetine had been administered 2 ± 4 days earlier (Figure 1 ). This eect is probably due to the existence of residual drug (¯uoxetine or nor¯uoxetine) in the tissue interfering with the binding parameters 7 days after uoxetine administration (Figure 3 ). The long-lasting neuroprotective eect of¯uoxetine appears to be closely related to the presence in the brain of uoxetine and its active and major metabolite nor¯uoxetine, whose presence was still detectable for up to 7 days after administration of¯uoxetine. Both¯uoxetine and nor¯uox-etine act primarily as 5-HT uptake inhibitors (Bolden-Watson & Richelson, 1993; Wong et al., 1993; Sanchez & Hyttel, 1999) and both have similar ecacy as 5-HT uptake inhibitors (Wong et al., 1993) . Since the compounds have similar potency, it was possible to plot the concentration of [¯uoxetine+nor¯uoxetine] in nmol g 71 versus the degree of protection seen over time (using the loss in 5-HT content in cortex). This revealed a simple hyperbolic plot indicating that protection probably relates to tissue drug concentration (Figure 7) .
A plot of the changes in K D value versus concentration of [¯uoxetine+nor¯uoxetine] revealed, not unexpectedly, that there is a linear relationship between the combined concentration of these two highly liposoluble drugs and the K D value (r=0.99). There was also a reasonably linear relationship between the K D and B max value at every time point studied (r=0.91). It is probable that the B max change seen also relates to the presence of the drug interfering with the binding analysis rather than any down regulation of the receptor. This interpretation would be consistent with the failure of others to ®nd down regulation of the uptake site even on chronic administration of 5-HT uptake inhibitor compounds (Cheetham et al., 1993; Dean et al., 1997) . However we cannot rule out totally that a down regulation of the uptake site has occurred.
What appears clear is that a de®ned concentration of the drug must be present in the tissue to inhibit uptake and thereby provide neuroprotection. This view is supported by Fluoxetine not only provided long-lasting protection against the long-term neurotoxicity induced by MDMA but , i.p.) between 4 and 24 h before p-chloroamphetamine completely prevented the reduction of the cortical 5-HT concentration induced by pchloroamphetamine 4 h later. This eect was smaller when the pretreatment interval was 48 h (Fuller et al., 1975) .
There are several lines of evidence indicating that the continuous presence of selective 5-HT uptake inhibitors tends to produce changes in the function of the transporter within minutes Benmansour et al., 1999; Ramamoorthy et al., 1998) and that the changes are due to protein kinase C (PKC) activation in a similar way to that occurring for the 5-HT receptors (Qian et al., 1997) . PKC activation in turns leads to transporter phosphorylation, transporter redistribution from the cell surface (sequestration) and loss of functional uptake activity. In contrast to 5-HT and amphetamines, antidepressants facilitate the 5-HT transporter phosphorylation and block 5-HT uptake (Ramamoorthy & Blakely, 1999) . Since MDMA is a substrate for the 5-HT transporter, an internalization of cell-surface transporter protein and therefore, a decrease in the density of transporter proteins in the cell membrane induced by the presence of¯uoxetine or nor¯uoxetine, could involve a signi®cant and lasting blockade in the uptake of MDMA or most likely of a metabolic product to the presynaptic 5-HT nerve terminals (Esteban et al., 2001) .
Two and four days after¯uoxetine administration, there is a decrease in brain 5-HIAA concentration whereas 5-HT content remains unaltered. This eect, previously described by others (Baldessarini et al., 1992) , is probably due to decreased 5-HT synthesis resulting from compensatory changes initiated by the increase in the synaptic 5-HT concentration (Bymaster & Wong, 1974) . However, a reduction in 5-HT synthesis following¯uoxetine administration is not the cause of¯uoxetine-induced neuroprotection since administration of the tryptophan hydroxylase inhibitor p-chlorophenylalanine (PCPA) does not in¯uence the MDMA-induced decrease in cortical 5-HT uptake sites (Brodkin et al., 1993) .
All current evidence suggests that the neurotoxicity of MDMA is not due to the parent compound but to a toxic metabolite probably formed peripherally. Intracerebral administration of MDMA at a dose that produced a concentration similar or higher than that reached following a neurotoxic dose of MDMA (15 mg kg
71
) given peripherally, does not produce neurotoxic damage (Esteban et al., 2001) . There is evidence that intrastriatal or intracortical administration of glutathione and N-acetylcysteine conjugates of a-methyldopamine (a major metabolite of MDMA) causes signi®cant decreases in striatal and cortical 5-HT concentrations 7 days later (Bai et al., 1999) . Nevertheless, the role for these compounds on MDMA neurotoxicity remains to be determined.
It is well known that in Dark Agouti rats MDMA is metabolized by CYP2D1, the rat equivalent to the human CYP2D6, and that¯uoxetine and its metabolite, nor¯uox-etine, are potent inhibitors of CYP2D6 (Hamelin et al., 1996) . In addition,¯uoxetine and nor¯uoxetine are detected in the brain several days after¯uoxetine injection. Therefore, it could be argued that the protective eect of¯uoxetine results from its ability to inhibit MDMA metabolism. This does not appear to be the case since¯uoxetine did not alter the concentration of MDMA in the brain. When MDMA was administered to rats pretreated with¯uoxetine 2 days earlier (a time when the concentration of both¯uoxetine and its metabolite are still high), the cortical MDMA levels observed 60 min later were similar to that found in rats not given¯uoxetine. We can state with some degree of con®dence that¯uoxetine does not prevent MDMA toxicity by inhibiting the metabolism of the drug. It thus seems likely that¯uoxetine and its major metabolite are preventing the entry of a neurotoxic metabolite of MDMA into the nerve ending.
What can also be stated unequivocally is that the neuroprotective eect of¯uoxetine or¯uvoxamine against MDMA toxicity is not related to an eect on body temperature. The hyperthermic response immediately following MDMA was similar in rats receiving saline or either uoxetine or¯uvoxamine. In addition, these data support the notion that the rise in rectal temperature induced by MDMA is not obviously related to its ability to increase 5-HT release (Mechan et al., 2000) .
In summary this study shows that the neuroprotective eect of¯uoxetine is due to the long term presence of either the parent compound or to its active metabolite, nor¯uox-etine in the brain. Both compounds block 5-HT transporter selectively, inhibit 5-HT uptake and presumably interfere with the entry of MDMA or a neurotoxic metabolite into the presynaptic nerve terminal.
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